Combining OVs with ICIs, including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, further amplifies T cell-mediated tumor clearance by exploiting VSV-induced immunogenic cell death, improving therapeutic outcomes [43,59,123]. Here, CTLA4 is linked to neoplasm.